Sorrento Therapeutics, Inc.
Chemically-Locked Bispecific Antibodies

Last updated:

Abstract:

Provided are bispecific antibody compounds having the Formula I: ##STR00001## wherein, FAB.sup.1, FAB.sup.2, and --X-- are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Axl, and are useful in the treatment of one or more conditions.

Status:
Application
Type:

Utility

Filling date:

26 Jan 2022

Issue date:

12 May 2022